Authors: Bing Bai HuiQiang Huang QingQing Cai XiaoXiao Wang QiChun Cai ZeXiao Lin Yan Gao Yi Xia Qing Bu Ying Guo
Publish Date: 2013/01/18
Volume: 30, Issue: 1, Pages: 350-
Abstract
The combination of gemcitabine G vinorelbine V and pegylated liposomal doxorubicin D has proved to be effective in relapsed Hodgkin’s lymphoma HL Its efficacy in nonHodgkin’s lymphoma NHL remains to be discussed We retrospectively evaluated the efficacy and toxicity of the doseadjusted gemcitabine vinorelbine liposomal doxorubicin GVD in 14day schedule in 35 heavily pretreated patients with relapsed and refractory aggressive NHL or HL Treatment consisted of G 800 mg/m2 intravenous iv on day 1 V 15 mg/m2 iv on day 1 D 20 mg/m2 iv on day 1 repeated for 14 days Patients responded to GVD proceeded to subsequent autologous stem cell transplantation The objective response rate ORR was 486 with 314 complete remission A higher ORR was observed in patients with HL than in patients with NHL 800 vs 360 P = 0023 With a median followup of 26 months the estimated median progressionfree survival and overall survival were 5 range 1–73 months and 36 months range 2–73 months respectively The estimated 5year survival rate was 446 95 confidence interval 281–611 Toxicities were mild grade 3/4 neutropenia 343 thrombocytopenia 57 Our results suggest that the doseadjusted GVD in 14day schedule is effective and well tolerated in patients with refractory and relapsed HL and aggressive NHL The potential longterm survival in NHL is promising
Keywords: